Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other financing activities (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Other financing activities for 6 consecutive years, with $4881.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other financing activities changed N/A year-over-year to $4881.0, compared with a TTM value of $29795.0 through Sep 2025, changed N/A, and an annual FY2025 reading of $11205.0, down 55.06% over the prior year.
  • Other financing activities was $4881.0 for Q3 2025 at SAB Biotherapeutics, up from $2072.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $349115.0 in Q1 2021 and bottomed at -$201477.0 in Q4 2021.
  • Average Other financing activities over 5 years is $11540.6, with a median of $3655.5 recorded in 2023.
  • The sharpest move saw Other financing activities tumbled 351.43% in 2021, then surged 980.0% in 2024.
  • Year by year, Other financing activities stood at -$201477.0 in 2021, then skyrocketed by 134.32% to $69141.0 in 2022, then tumbled by 96.49% to $2430.0 in 2023, then surged by 740.0% to $20412.0 in 2024, then tumbled by 76.09% to $4881.0 in 2025.
  • Business Quant data shows Other financing activities for SABS at $4881.0 in Q3 2025, $2072.0 in Q1 2025, and $20412.0 in Q1 2024.